Single Cell Sequencing Market Forecasts to 2032 – Global Analysis By Product (Instruments, Reagents & Consumables, Software & Services and Other Products), Cell Type, Workflow, Technology, Application, End User and By Geography
Description
According to Stratistics MRC, the Global Single Cell Sequencing Market is accounted for $2.1 billion in 2025 and is expected to reach $5.4 billion by 2032 growing at a CAGR of 14.2% during the forecast period. Single-cell sequencing is an advanced genomic technique used to analyze the genetic material of individual cells, providing detailed insights into cellular diversity, gene expression, and function. Unlike traditional bulk sequencing, which averages signals from multiple cells, single-cell sequencing captures variations at the single-cell level, revealing heterogeneity within tissues and complex biological systems. This technology involves isolating individual cells, amplifying their nucleic acids, and sequencing DNA or RNA to study genomic, transcriptomic, or epigenomic profiles. It plays a crucial role in understanding developmental biology, cancer evolution, immune responses, and neurological disorders, enabling precision medicine and targeted therapeutic advancements.
Market Dynamics:
Driver:
Rising demand in precision medicine, oncology & immunology
Scientists are using single-cell platforms to uncover cellular heterogeneity, identify rare cell populations, and map immune responses in cancer and autoimmune diseases. Integration with spatial transcriptomics and multi-omics tools is improving resolution and biological insight. Pharmaceutical companies are leveraging single-cell data to optimize drug targets and biomarker discovery. These capabilities are propelling innovation across personalized medicine and translational research.
Restraint:
Complexity of data analysis and bioinformatics bottlenecks
High-dimensional datasets require advanced computational tools and skilled personnel for preprocessing, normalization, and interpretation. Lack of standardized pipelines and annotation frameworks slows reproducibility and cross-study comparison. Storage and processing costs remain high for large-scale experiments. Smaller labs and hospitals face challenges in integrating single-cell workflows into existing infrastructure. These constraints continue to hinder operational efficiency and platform adoption.
Opportunity:
Increasing research funding & government support
National genomics programs and cancer moonshots are allocating resources to single-cell platforms for disease mapping and therapeutic development. Public-private partnerships are supporting tool development, training, and data sharing across academic and clinical networks. Investment in open-source bioinformatics and cloud-based analysis platforms is improving accessibility and scalability. These trends are fostering long-term growth across basic science, diagnostics, and drug development.
Threat:
Lack of standardization and reproducibility
Variability in sample preparation, library construction, and sequencing depth can lead to inconsistent results. Absence of universal benchmarks and reference datasets complicates cross-platform comparison. Reproducibility challenges slow regulatory acceptance and clinical translation. Journals and funding bodies are increasing scrutiny around data quality and transparency. These risks continue to hamper confidence and downstream utility in high-impact applications.
Covid-19 Impact:
The pandemic accelerated interest in single cell sequencing as researchers sought to understand immune responses and viral pathogenesis. Single-cell platforms were used to profile COVID-19 patient samples and identify immune signatures linked to severity and recovery. Investment in infectious disease research and immunology surged across public and private sectors. Remote collaboration and cloud-based analysis tools gained traction during lab closures. Post-pandemic strategies now include single-cell sequencing as part of long-term preparedness and biomedical innovation. These shifts are accelerating integration into clinical and translational workflows.
The instruments segment is expected to be the largest during the forecast period
The instruments segment is expected to account for the largest market share during the forecast period due to their foundational role in enabling sample isolation, library preparation, and sequencing across single-cell workflows. Platforms such as microfluidics, droplet-based systems, and laser capture technologies are being adopted across academic and commercial labs. Vendors are offering modular instruments that support multi-omics and spatial integration. Demand for high-throughput, low-input systems is rising across oncology, neurology, and stem cell research. These capabilities are boosting instrument segment dominance across global sequencing infrastructure.
The downstream data analysis segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the downstream data analysis segment is predicted to witness the highest growth rate as researchers seek scalable and interpretable insights from high-dimensional single-cell datasets. Bioinformatics platforms are enabling clustering, trajectory inference, and differential expression analysis across cell populations. Integration with machine learning and cloud computing is improving speed and reproducibility. Vendors are launching user-friendly interfaces and automated pipelines for non-specialist users. Demand for real-time, collaborative analysis is rising across multi-site studies and translational programs. These dynamics are accelerating growth across data-centric sequencing applications.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share due to its advanced research infrastructure, funding ecosystem, and vendor presence. U.S. institutions are deploying single-cell platforms across cancer centers, academic labs, and biotech firms. NIH and private foundations are funding large-scale cell atlas and immunology projects. Presence of leading instrument and software vendors is driving innovation and standardization. Regulatory clarity and clinical trial integration are supporting translational adoption. These factors are boosting North America’s leadership in single-cell sequencing deployment.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as genomics investment, healthcare digitization, and academic expansion converge. Countries like China, Japan, South Korea, and India are scaling single-cell platforms across oncology, infectious disease, and stem cell research. Government-backed programs are supporting infrastructure, training, and data sharing across institutions. Local vendors are launching affordable instruments and cloud-based analysis tools tailored to regional needs. Demand for precision diagnostics and personalized therapies is rising across public and private sectors. These trends are accelerating regional growth across single-cell sequencing ecosystems.
Key players in the market
Some of the key players in Single Cell Sequencing Market include 10x Genomics, Illumina, Thermo Fisher Scientific, QIAGEN, Fluidigm, Takara Bio, Bio-Rad Laboratories, Roche, BGI Group / Complete Genomics, Parse Biosciences, Singleron Biotechnologies, Mission Bio, STRATEC SE and Agilent Technologies.
Key Developments:
In April 2025, 10x Genomics introduced new enhancements to its Chromium and Visium platforms, supporting multi-omic single-cell analysis. These upgrades enabled researchers to simultaneously profile gene expression, epigenetic markers, and spatial context, improving resolution and throughput for oncology, immunology, and neuroscience applications.
In August 2024, Illumina announced a new research partnership with the Broad Institute of MIT and Harvard to accelerate single-cell sequencing applications. The collaboration focuses on multiomics integration, enabling researchers to combine transcriptomic, epigenomic, and spatial data for deeper insights into cell function and disease mechanisms.
Products Covered:
• Instruments
• Reagents & Consumables
• Software & Services
• Other Products
Cell Types Covered:
• Human Cells
• Animal Cells
• Microbial Cells
• Other Cell Types
Workflows Covered:
• Sample Preparation
• Single Cell Isolation
• Library Preparation
• Sequencing
• Downstream Data Analysis
• Other Workflows
Technologies Covered:
• Next-Generation Sequencing (NGS)
• Single-Molecule Real-Time (SMRT) Sequencing
• Microfluidics
• PCR-Based Techniques
• Flow Cytometry
• Microscopy-Based Methods
• Other Technologies
Applications Covered:
• Oncology
• Immunology
• Neurology
• Stem Cell Research
• Non-Invasive Prenatal Testing (NIPT)
• In Vitro Fertilization (IVF)
• Other Applications
End Users Covered:
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Clinical & Diagnostic Labs
• Contract Research Organizations (CROs)
• Other End-Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Market Dynamics:
Driver:
Rising demand in precision medicine, oncology & immunology
Scientists are using single-cell platforms to uncover cellular heterogeneity, identify rare cell populations, and map immune responses in cancer and autoimmune diseases. Integration with spatial transcriptomics and multi-omics tools is improving resolution and biological insight. Pharmaceutical companies are leveraging single-cell data to optimize drug targets and biomarker discovery. These capabilities are propelling innovation across personalized medicine and translational research.
Restraint:
Complexity of data analysis and bioinformatics bottlenecks
High-dimensional datasets require advanced computational tools and skilled personnel for preprocessing, normalization, and interpretation. Lack of standardized pipelines and annotation frameworks slows reproducibility and cross-study comparison. Storage and processing costs remain high for large-scale experiments. Smaller labs and hospitals face challenges in integrating single-cell workflows into existing infrastructure. These constraints continue to hinder operational efficiency and platform adoption.
Opportunity:
Increasing research funding & government support
National genomics programs and cancer moonshots are allocating resources to single-cell platforms for disease mapping and therapeutic development. Public-private partnerships are supporting tool development, training, and data sharing across academic and clinical networks. Investment in open-source bioinformatics and cloud-based analysis platforms is improving accessibility and scalability. These trends are fostering long-term growth across basic science, diagnostics, and drug development.
Threat:
Lack of standardization and reproducibility
Variability in sample preparation, library construction, and sequencing depth can lead to inconsistent results. Absence of universal benchmarks and reference datasets complicates cross-platform comparison. Reproducibility challenges slow regulatory acceptance and clinical translation. Journals and funding bodies are increasing scrutiny around data quality and transparency. These risks continue to hamper confidence and downstream utility in high-impact applications.
Covid-19 Impact:
The pandemic accelerated interest in single cell sequencing as researchers sought to understand immune responses and viral pathogenesis. Single-cell platforms were used to profile COVID-19 patient samples and identify immune signatures linked to severity and recovery. Investment in infectious disease research and immunology surged across public and private sectors. Remote collaboration and cloud-based analysis tools gained traction during lab closures. Post-pandemic strategies now include single-cell sequencing as part of long-term preparedness and biomedical innovation. These shifts are accelerating integration into clinical and translational workflows.
The instruments segment is expected to be the largest during the forecast period
The instruments segment is expected to account for the largest market share during the forecast period due to their foundational role in enabling sample isolation, library preparation, and sequencing across single-cell workflows. Platforms such as microfluidics, droplet-based systems, and laser capture technologies are being adopted across academic and commercial labs. Vendors are offering modular instruments that support multi-omics and spatial integration. Demand for high-throughput, low-input systems is rising across oncology, neurology, and stem cell research. These capabilities are boosting instrument segment dominance across global sequencing infrastructure.
The downstream data analysis segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the downstream data analysis segment is predicted to witness the highest growth rate as researchers seek scalable and interpretable insights from high-dimensional single-cell datasets. Bioinformatics platforms are enabling clustering, trajectory inference, and differential expression analysis across cell populations. Integration with machine learning and cloud computing is improving speed and reproducibility. Vendors are launching user-friendly interfaces and automated pipelines for non-specialist users. Demand for real-time, collaborative analysis is rising across multi-site studies and translational programs. These dynamics are accelerating growth across data-centric sequencing applications.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share due to its advanced research infrastructure, funding ecosystem, and vendor presence. U.S. institutions are deploying single-cell platforms across cancer centers, academic labs, and biotech firms. NIH and private foundations are funding large-scale cell atlas and immunology projects. Presence of leading instrument and software vendors is driving innovation and standardization. Regulatory clarity and clinical trial integration are supporting translational adoption. These factors are boosting North America’s leadership in single-cell sequencing deployment.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as genomics investment, healthcare digitization, and academic expansion converge. Countries like China, Japan, South Korea, and India are scaling single-cell platforms across oncology, infectious disease, and stem cell research. Government-backed programs are supporting infrastructure, training, and data sharing across institutions. Local vendors are launching affordable instruments and cloud-based analysis tools tailored to regional needs. Demand for precision diagnostics and personalized therapies is rising across public and private sectors. These trends are accelerating regional growth across single-cell sequencing ecosystems.
Key players in the market
Some of the key players in Single Cell Sequencing Market include 10x Genomics, Illumina, Thermo Fisher Scientific, QIAGEN, Fluidigm, Takara Bio, Bio-Rad Laboratories, Roche, BGI Group / Complete Genomics, Parse Biosciences, Singleron Biotechnologies, Mission Bio, STRATEC SE and Agilent Technologies.
Key Developments:
In April 2025, 10x Genomics introduced new enhancements to its Chromium and Visium platforms, supporting multi-omic single-cell analysis. These upgrades enabled researchers to simultaneously profile gene expression, epigenetic markers, and spatial context, improving resolution and throughput for oncology, immunology, and neuroscience applications.
In August 2024, Illumina announced a new research partnership with the Broad Institute of MIT and Harvard to accelerate single-cell sequencing applications. The collaboration focuses on multiomics integration, enabling researchers to combine transcriptomic, epigenomic, and spatial data for deeper insights into cell function and disease mechanisms.
Products Covered:
• Instruments
• Reagents & Consumables
• Software & Services
• Other Products
Cell Types Covered:
• Human Cells
• Animal Cells
• Microbial Cells
• Other Cell Types
Workflows Covered:
• Sample Preparation
• Single Cell Isolation
• Library Preparation
• Sequencing
• Downstream Data Analysis
• Other Workflows
Technologies Covered:
• Next-Generation Sequencing (NGS)
• Single-Molecule Real-Time (SMRT) Sequencing
• Microfluidics
• PCR-Based Techniques
• Flow Cytometry
• Microscopy-Based Methods
• Other Technologies
Applications Covered:
• Oncology
• Immunology
• Neurology
• Stem Cell Research
• Non-Invasive Prenatal Testing (NIPT)
• In Vitro Fertilization (IVF)
• Other Applications
End Users Covered:
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Clinical & Diagnostic Labs
• Contract Research Organizations (CROs)
• Other End-Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Table of Contents
200 Pages
- 1 Executive Summary
- 2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
- 3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 Technology Analysis
- 3.8 Application Analysis
- 3.9 End User Analysis
- 3.10 Emerging Markets
- 3.11 Impact of Covid-19
- 4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
- 5 Global Single Cell Sequencing Market, By Product
- 5.1 Introduction
- 5.2 Instruments
- 5.3 Reagents & Consumables
- 5.4 Software & Services
- 5.5 Other Products
- 6 Global Single Cell Sequencing Market, By Cell Type
- 6.1 Introduction
- 6.2 Human Cells
- 6.3 Animal Cells
- 6.4 Microbial Cells
- 6.5 Other Cell Types
- 7 Global Single Cell Sequencing Market, By Workflow
- 7.1 Introduction
- 7.2 Sample Preparation
- 7.3 Single Cell Isolation
- 7.4 Library Preparation
- 7.5 Sequencing
- 7.6 Downstream Data Analysis
- 7.7 Other Workflows
- 8 Global Single Cell Sequencing Market, By Technology
- 8.1 Introduction
- 8.2 Next-Generation Sequencing (NGS)
- 8.3 Single-Molecule Real-Time (SMRT) Sequencing
- 8.4 Microfluidics
- 8.5 PCR-Based Techniques
- 8.6 Flow Cytometry
- 8.7 Microscopy-Based Methods
- 8.8 Other Technologies
- 9 Global Single Cell Sequencing Market, By Application
- 9.1 Introduction
- 9.2 Oncology
- 9.3 Immunology
- 9.4 Neurology
- 9.5 Stem Cell Research
- 9.6 Non-Invasive Prenatal Testing (NIPT)
- 9.7 In Vitro Fertilization (IVF)
- 9.8 Other Applications
- 10 Global Single Cell Sequencing Market, By End User
- 10.1 Introduction
- 10.2 Academic & Research Institutes
- 10.3 Pharmaceutical & Biotechnology Companies
- 10.4 Clinical & Diagnostic Labs
- 10.5 Contract Research Organizations (CROs)
- 10.6 Other End-Users
- 11 Global Single Cell Sequencing Market, By Geography
- 11.1 Introduction
- 11.2 North America
- 11.2.1 US
- 11.2.2 Canada
- 11.2.3 Mexico
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 Italy
- 11.3.4 France
- 11.3.5 Spain
- 11.3.6 Rest of Europe
- 11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 New Zealand
- 11.4.6 South Korea
- 11.4.7 Rest of Asia Pacific
- 11.5 South America
- 11.5.1 Argentina
- 11.5.2 Brazil
- 11.5.3 Chile
- 11.5.4 Rest of South America
- 11.6 Middle East & Africa
- 11.6.1 Saudi Arabia
- 11.6.2 UAE
- 11.6.3 Qatar
- 11.6.4 South Africa
- 11.6.5 Rest of Middle East & Africa
- 12 Key Developments
- 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 12.2 Acquisitions & Mergers
- 12.3 New Product Launch
- 12.4 Expansions
- 12.5 Other Key Strategies
- 13 Company Profiling
- 13.1 10x Genomics
- 13.2 Illumina
- 13.3 Thermo Fisher Scientific
- 13.4 QIAGEN
- 13.5 Fluidigm
- 13.6 Takara Bio
- 13.7 Bio-Rad Laboratories
- 13.8 Roche
- 13.9 BGI Group / Complete Genomics
- 13.10 Parse Biosciences
- 13.11 Singleron Biotechnologies
- 13.12 Mission Bio
- 13.13 STRATEC SE
- 13.14 Agilent Technologies
- List of Tables
- Table 1 Global Single Cell Sequencing Market Outlook, By Region (2024-2032) ($MN)
- Table 2 Global Single Cell Sequencing Market Outlook, By Product (2024-2032) ($MN)
- Table 3 Global Single Cell Sequencing Market Outlook, By Instruments (2024-2032) ($MN)
- Table 4 Global Single Cell Sequencing Market Outlook, By Reagents & Consumables (2024-2032) ($MN)
- Table 5 Global Single Cell Sequencing Market Outlook, By Software & Services (2024-2032) ($MN)
- Table 6 Global Single Cell Sequencing Market Outlook, By Other Products (2024-2032) ($MN)
- Table 7 Global Single Cell Sequencing Market Outlook, By Cell Type (2024-2032) ($MN)
- Table 8 Global Single Cell Sequencing Market Outlook, By Human Cells (2024-2032) ($MN)
- Table 9 Global Single Cell Sequencing Market Outlook, By Animal Cells (2024-2032) ($MN)
- Table 10 Global Single Cell Sequencing Market Outlook, By Microbial Cells (2024-2032) ($MN)
- Table 11 Global Single Cell Sequencing Market Outlook, By Other Cell Types (2024-2032) ($MN)
- Table 12 Global Single Cell Sequencing Market Outlook, By Workflow (2024-2032) ($MN)
- Table 13 Global Single Cell Sequencing Market Outlook, By Sample Preparation (2024-2032) ($MN)
- Table 14 Global Single Cell Sequencing Market Outlook, By Single Cell Isolation (2024-2032) ($MN)
- Table 15 Global Single Cell Sequencing Market Outlook, By Library Preparation (2024-2032) ($MN)
- Table 16 Global Single Cell Sequencing Market Outlook, By Sequencing (2024-2032) ($MN)
- Table 17 Global Single Cell Sequencing Market Outlook, By Downstream Data Analysis (2024-2032) ($MN)
- Table 18 Global Single Cell Sequencing Market Outlook, By Other Workflows (2024-2032) ($MN)
- Table 19 Global Single Cell Sequencing Market Outlook, By Technology (2024-2032) ($MN)
- Table 20 Global Single Cell Sequencing Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
- Table 21 Global Single Cell Sequencing Market Outlook, By Single-Molecule Real-Time (SMRT) Sequencing (2024-2032) ($MN)
- Table 22 Global Single Cell Sequencing Market Outlook, By Microfluidics (2024-2032) ($MN)
- Table 23 Global Single Cell Sequencing Market Outlook, By PCR-Based Techniques (2024-2032) ($MN)
- Table 24 Global Single Cell Sequencing Market Outlook, By Flow Cytometry (2024-2032) ($MN)
- Table 25 Global Single Cell Sequencing Market Outlook, By Microscopy-Based Methods (2024-2032) ($MN)
- Table 26 Global Single Cell Sequencing Market Outlook, By Other Technologies (2024-2032) ($MN)
- Table 27 Global Single Cell Sequencing Market Outlook, By Application (2024-2032) ($MN)
- Table 28 Global Single Cell Sequencing Market Outlook, By Oncology (2024-2032) ($MN)
- Table 29 Global Single Cell Sequencing Market Outlook, By Immunology (2024-2032) ($MN)
- Table 30 Global Single Cell Sequencing Market Outlook, By Neurology (2024-2032) ($MN)
- Table 31 Global Single Cell Sequencing Market Outlook, By Stem Cell Research (2024-2032) ($MN)
- Table 32 Global Single Cell Sequencing Market Outlook, By Non-Invasive Prenatal Testing (NIPT) (2024-2032) ($MN)
- Table 33 Global Single Cell Sequencing Market Outlook, By In Vitro Fertilization (IVF) (2024-2032) ($MN)
- Table 34 Global Single Cell Sequencing Market Outlook, By Other Applications (2024-2032) ($MN)
- Table 35 Global Single Cell Sequencing Market Outlook, By End User (2024-2032) ($MN)
- Table 36 Global Single Cell Sequencing Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
- Table 37 Global Single Cell Sequencing Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
- Table 38 Global Single Cell Sequencing Market Outlook, By Clinical & Diagnostic Labs (2024-2032) ($MN)
- Table 39 Global Single Cell Sequencing Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)
- Table 40 Global Single Cell Sequencing Market Outlook, By Other End-Users (2024-2032) ($MN)
- Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
